Home / Products / Antibiotics / PROXINA-CL
Click image to inspect pack details
Antibiotics Marketed by Aerochem Neutron

PROXINA-CL

Formulation Code AC-472
Commercial Status Active Product Information Available

Product Overview & Formulation Profile

Description

Cefpodoxime Proxetil 200 mg + Clavulanic Acid 125 mg Tablets

PROXINA-CL combines cefpodoxime proxetil, an oral third-generation cephalosporin antibiotic, with clavulanic acid, a beta-lactamase inhibitor.

Cefpodoxime acts by inhibiting bacterial cell-wall synthesis. Clavulanic acid inhibits certain beta-lactamase enzymes that can otherwise inactivate susceptible beta-lactam antibiotics.

The combination has been approved in India for selected respiratory tract, uncomplicated skin and urinary tract infections. Its use should be guided by clinical assessment, bacterial susceptibility and current antimicrobial treatment recommendations.

The addition of clavulanic acid does not overcome all mechanisms of bacterial resistance. Appropriate antibiotic selection remains essential.

Dosage Form: Tablets
Packing: 10 x 6 Strip Pack

Prescription medicine. To be used under the supervision of a registered medical practitioner.

Composition & Formulation Details

Features

  • Two-component antibacterial formulation: Combines cefpodoxime with clavulanic acid.

  • Cephalosporin action: Cefpodoxime inhibits bacterial cell-wall synthesis.

  • Beta-lactamase inhibition: Clavulanic acid inhibits certain bacterial beta-lactamase enzymes.

  • Complementary mechanisms: The components address bacterial cell-wall synthesis and selected beta-lactamase-mediated resistance mechanisms.

  • Clinical selection: Treatment should consider the likely pathogen, susceptibility findings, patient factors and relevant prescribing guidelines.

Conditions

Therapeutic Indications

  • Upper Respiratory Tract Infections (URTI): Treatment of susceptible bacterial upper respiratory tract infections.

  • Lower Respiratory Tract Infections (LRTI): Treatment of susceptible bacterial lower respiratory tract infections.

  • Uncomplicated Skin Infections: Treatment of uncomplicated bacterial skin infections caused by susceptible organisms.

  • Urinary Tract Infections (UTI): Treatment of susceptible bacterial urinary tract infections.

Use should follow the approved product label, clinical assessment and local antimicrobial susceptibility patterns. Not intended for viral infections.

Professional Product Enquiries

Verified product information, formulation specifications, and commercial supply pathways for registered healthcare professionals, institutions, and trade partners.

Product Information

Review verified active composition, strength, dosage form, and packaging details on this page.

View Specifications

Healthcare Professional Enquiry

Request formulation literature, technical specifications, or product communication from our commercial team.

Submit Product Enquiry

Commercial Supply Enquiry

Connect regarding institutional supply requirements, trade distribution, or third-party contract manufacturing.

Commercial Enquiry

Professional Product Information

This product information is intended for registered healthcare professionals, medical practitioners, and authorized distribution partners. Product manufacturing is coordinated through eligible facility partners under applicable licences.

Product Enquiry

Request Formulation Details

Request information about PROXINA-CL for professional use.

Please enter the numeric sum to verify you are a human visitor.
Therapeutic Alternatives

Related Formulations

SULTAVIN Formulation
AEROCLAV -625 Formulation
AEROFLOX 200 Formulation
A.G 250 Formulation
Product Information

Need specifications for this formulation?

Request verified product information for professional use, or send a separate business enquiry for manufacturing or partnership discussions.

WhatsApp: +91 9512047000